Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Dec;26(4):218-222.
doi: 10.1055/s-0037-1601871. Epub 2017 Apr 16.

Vitronectin and Urokinase-Type Plasminogen Activator Gene Expression Levels Are Increased in Patients with Coronary Artery In-Stent Restenosis

S M Shafiee  1 , F Noorabad-Ghahroodi  1 , A Amirfarhangi  2 , S R Hosseini-Fard  3 , Z Sharifi  4 , M Najafi  5
Affiliations

Vitronectin and Urokinase-Type Plasminogen Activator Gene Expression Levels Are Increased in Patients with Coronary Artery In-Stent Restenosis

S M Shafiee et al. Int J Angiol. 2017 Dec.

Abstract

Neointimal hyperplasia is known as a main factor contributing to in-stent restenosis (ISR). Monocytes may play a central role in vessel restenosis process after stent implantation. The aim of this study was to investigate the relationships between the urokinase-type plasminogen activator (PLAU) and vitronectin (Vtn) gene expression levels in peripheral blood mononuclear cell samples isolated from whole blood of 66 patients undergoing coronary artery angiography (22 controls, stenosis < 0.05%; 22 with stent no-restenosis and stenosis < 70%; and 22 with ISR and stenosis > 70%). The Vtn and PLAU gene expression levels were measured by real-time quantitative polymerase chain reaction technique. The age- and gender-independent increases in the expression levels of Vtn (17-fold; p < 0.001) and PLAU (27-fold; p < 0.0001) genes were found in the patients with ISR as compared with the control group. The results suggested that the Vtn and PLAU genes may be involved in the coronary artery ISR.

Keywords: in-stent restenosis; urokinase-type plasminogen activator; vitronectin.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Urokinase-type plasminogen activator gene expression levels in study groups. Control (stenosis < 5%), stent no-restenosis (SNR) < 70%, and in-stent restenosis (ISR) >70%. ISR versus control and SNR; p  < 0.0001.
Fig. 2
Fig. 2
Vitronectin gene expression levels in study groups. Control (stenosis < 5%), stent no-restenosis (SNR) <70%, in-stent restenosis (ISR) >70%. ISR versus control and SNR; p  < 0.001.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Yang Z K, Shen Y, Hu J et al.Impact of coronary collateral circulation on angiographic in-stent restenosis in patients with stable coronary artery disease and chronic total occlusion. Int J Cardiol. 2017;227:485–489. - PubMed
    1. Fischman D L, Leon M B, Baim D S et al.A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med. 1994;331(08):496–501. - PubMed
    1. Indolfi C, Pavia M, Angelillo I F. Drug-eluting stents versus bare metal stents in percutaneous coronary interventions (a meta-analysis) Am J Cardiol. 2005;95(10):1146–1152. - PubMed
    1. Denes L, Entz L, Jancsik V. Restenosis and therapy. Int J Vasc Med. 2012;2012:406236. - PMC - PubMed
    1. Serruys P W, de Jaegere P, Kiemeneij F et al.A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med. 1994;331(08):489–495. - PubMed